PUBLISHER: The Insight Partners | PRODUCT CODE: 1482004
PUBLISHER: The Insight Partners | PRODUCT CODE: 1482004
The Europe vitamin K2 market is expected to grow from US$ 53.27 million in 2022 to US$ 423.10 million by 2030. It is estimated to grow at a CAGR of 29.6% from 2022 to 2030.
Growing Cases of Osteoporosis Bone Deformation in Adults and Newborns Fuels Europe Vitamin K2 Market
Osteoporosis is an increasingly common health issue affecting adults and babies, a disorder marked by weakening and fragile bones. According to International Osteoporosis Foundation 2022, globally osteoporosis causes more than 8.9 million fractures every year resulting in osteoporotic fracture in every 3 seconds. Medical professionals are concerned about the surge in osteoporosis-related bone distortion cases. As per recent studies from Research Gate, the potential advantages of vitamin K2 include supporting bone health and possibly reducing the consequences of osteoporosis.
Vitamin K2 is a lesser-known vitamin K essential for maintaining healthy calcium metabolism and bone density. It stimulates proteins that transfer calcium from the bloodstream into the bones to ensure adequate mineralization and strength. The nutrient aid in avoiding osteoporosis-related bone fractures and deformities by improving calcium absorption. Adult osteoporosis cases frequently result from hormonal changes, age-related bone loss, or inadequate food intake. Vitamin K2 supplementation has demonstrated promising outcomes in enhancing bone mineral density and lowering fracture risk among adults. In addition, women are the main target for bone health products due to their higher incidence of osteoporosis. The increasing incidence of osteoporosis-related difficulties continues to be a key focus for functional foods and supplements such as calcium and vitamin D are the primary components supporting bone health. Calcium is the main mineral component of bones, while vitamin helps with calcium absorption. changes However, as consumers are becoming more aware of the benefits of vitamin K2, its availability in foods and supplements is rising. In addition, it has been proposed that vitamin K2 aids in reducing the activity of osteoclast cells, which are responsible for bone deterioration, further protecting bone integrity.
Newborns can develop osteoporosis, especially preterm babies. They are more prone to fractures since their bones are immature and weak. Vitamin K2 improves bone growth and lessens the likelihood of bone abnormalities in the therapy regimens for these infants. Their skeletal development is accelerated by vitamin K2 supplementation, which supports the naturally occurring processes during the early stages of life. Thus, the growing number of adult and neonatal incidences of osteoporosis-related bone abnormalities creates the urgent need for efficient preventative measures and treatment approaches. Hence, vitamin K2 supplementation acts as a potential supplementary therapy that helps with calcium metabolism, bone mineralization, and the prevention of fractures. All these factors are driving the market growth.
Europe Vitamin K2 Market Overview
The Europe vitamin K2 market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. The growth of the market is attributed to the increasing prevalence of CVD and growing cases of osteoporosis bone deformation in adults and newborns. However, the limited awareness regarding benefits of vitamin K2 hinders the market growth. Countries such as Germany and Italy are expected to be the most significant contributors to market growth in the region and countries such as France, the UK, and Spain are likely to have growth opportunities for vitamin K2. The European vitamin K2 market is expected to grow owing to the surge in non-invasive aesthetic treatments such as non-surgical skin tightening and non-surgical fat reductions due to increased awareness of aesthetic appearance. Furthermore, the medical devices industry developments and the rising numbers of aesthetic clinics may offer vital growth opportunities.
Europe Vitamin K2 Market Revenue and Forecast to 2030 (US$ Million)
Europe Vitamin K2 Market Segmentation
The Europe vitamin K2 market is segmented into product, dosage forms, source, application, and country.
Based on product, the Europe vitamin K2 market is segmented into MK-4, MK-7, and combination drugs. The MK-7 segment held the largest share of the Europe vitamin K2 market in 2022.
Based on dosage forms, the Europe vitamin K2 market is segmented into capsules & tablets, powder, and oils. The powder segment held the largest share of the Europe vitamin K2 market in 2022.
Based on source, the Europe vitamin K2 market is segmented into natural and synthetic. The natural segment held a larger share of the Europe vitamin K2 market in 2022.
Based on application, the Europe vitamin K2 market is segmented into pharmaceuticals, nutraceuticals and food, and others. The pharmaceuticals segment held the largest share of the Europe vitamin K2 market in 2022.
Based on country, the Europe vitamin K2 market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vitamin K2 market in 2022.
Anderson Global Group LLC, Balchem Corp, BASF SE, Glanbia Plc, International Flavors & Fragrances Inc, Koninklijke DSM NV, Lesaffre et Cie SA, Lonza Group AG, and Novozymes AS are some of the leading companies operating in the Europe vitamin K2 market.